Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs MorphoSys AG Trends and Insights

Biotech Giants' SG&A Expenses: A Decade of Growth and Strategy

__timestampMorphoSys AGNeurocrine Biosciences, Inc.
Wednesday, January 1, 2014968900017986000
Thursday, January 1, 20151043100032480000
Friday, January 1, 2016961800068081000
Sunday, January 1, 201712348000169906000
Monday, January 1, 201828310241248932000
Tuesday, January 1, 201959336147354100000
Wednesday, January 1, 2020159145941433300000
Friday, January 1, 2021199800000583300000
Saturday, January 1, 202290225000752700000
Sunday, January 1, 202392538000887600000
Monday, January 1, 20241007200000
Loading chart...

Unveiling the hidden dimensions of data

SG&A Expenses: A Tale of Two Biotech Giants

In the competitive world of biotechnology, understanding financial trends is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Neurocrine Biosciences, Inc. and MorphoSys AG from 2014 to 2023. Over this period, Neurocrine Biosciences has consistently outpaced MorphoSys AG, with its SG&A expenses growing by nearly 500%, reaching a peak in 2023. In contrast, MorphoSys AG's expenses increased by approximately 850%, albeit from a smaller base, indicating a more aggressive expansion strategy. Notably, Neurocrine's expenses in 2023 were almost 10 times higher than in 2014, reflecting its significant market presence. Meanwhile, MorphoSys AG's expenses surged in 2020, suggesting strategic investments during the pandemic. These trends highlight the differing growth trajectories and strategic priorities of these two biotech leaders, offering valuable insights for investors and industry analysts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025